Eplerenone to slow blood vessel damage after kidney transplant
Treatments studied
Part of Heart & circulation, Kidney & urinary clinical trials.
This trial tests whether eplerenone can slow the progression of blood vessel (vasculature) problems in people who have had a kidney transplant. You may be eligible if you are older, stable on your transplant medicines, and have higher peripheral artery blood pressure readings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- Kidney transplant at least 1 year before starting the study
- Currently taking cyclosporine
- Your health and non–blood-pressure medicines have been stable for the last 3 months (and no rejection episode in the last 3 months)
- Your kidney function test (eGFR using CKD-EPI) is at least 30
- Your peripheral artery pressure (PAS) is 110 mmHg or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called finerenone can help protect kidney transplants from further damage. People who have had a kidney transplant and have protein in their urine may benefit from this treatment.
This Phase 2 study tests whether eplerenone can improve outcomes after a heart attack (or similar heart injury) when coronary angiography shows no blocked heart arteries. It focuses on people with added cardiovascular risk factors and evaluates how well the treatment works for heart recovery and strain on the heart.
This trial tests a new treatment for people with heart failure and severely reduced kidney function. It aims to see if the treatment can help protect both the heart and kidneys.
This study tests whether a structured diet and exercise program can lower heart disease risk in kidney transplant recipients. If you've had a stable transplant for at least 6 months and up to 10 years, you may be able to join.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
Hear when a new Kidney Transplantation for More Than One Year trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.